Invention Grant
![Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor](/docs/US/2021-08-17/US11091485B2/abs.jpg.600x600.jpg)
- Patent Title: Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
-
Application No.: US16619222Application Date: 2018-05-21
-
Publication No.: US11091485B2Publication Date: 2021-08-17
- Inventor: Bin Liu , Hang Cheng , Weiyan Xiong , Chenggang Zhang , Chengzhi Yu
- Applicant: SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
- Applicant Address: CN Jiangsu
- Assignee: SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
- Current Assignee: SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
- Current Assignee Address: CN Jiangsu
- Agency: McCarter & English, LLP
- Agent Xin Zhang
- Priority: CN201710368799.3 20170523
- International Application: PCT/CN2018/087665 WO 20180521
- International Announcement: WO2018/214846 WO 20181129
- Main IPC: C07D471/14
- IPC: C07D471/14 ; C07D519/00
![Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor](/abs-image/US/2021/08/17/US11091485B2/abs.jpg.150x150.jpg)
Abstract:
Provided is an imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.
Public/Granted literature
- US20200270251A1 IMIDAZO[1',2':1,6]PYRIDO[2,3-D]PYRIMIDINE COMPOUND AS PROTEIN KINASE INHIBITOR Public/Granted day:2020-08-27
Information query
